The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims and Hers is an online platform that connects patients with licensed healthcare professionals and offers treatments for a range of conditions, including hair loss and sexual wellness ...